GlassScriptPhysician profile
Michael S Drury
NPI 1568462893
$13,624.74
in general payments reported to CMS, 2019-2025
57 companies · $1,973 in 2025
The $1,973 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,889 · 2020: $1,042 · 2021: $2,937 · 2022: $1,608 · 2023: $1,818 · 2024: $2,357 · 2025: $1,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,045 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,044.95 |
| Education | $103.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,951.82 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,475.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,297.53 | 2020-2021 | |
| Glaxosmithkline, LLC. | $941.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $744.14 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $728.14 | 2019-2025 | |
| Amgen INC. | $727.71 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $720.57 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $523.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.62 | 2019-2025 | Jardiance |
| Abbott Laboratories | $429.50 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Lilly USA, LLC | $396.76 | 2019-2025 | Jardiance, Zepbound |
| Nestle Healthcare Nutrition INC. | $269.71 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $200.99 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $200.41 | 2021-2023 | Hetlioz |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Drury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.